Sensitizing tumor cells to immune-mediated cytotoxicity

Advances in Experimental Medicine and Biology

Volumn 601, Issue , 2007, Pages 163-171

  Shanker, Anil ^a   Sayers, Thomas ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; LIGAND; PROTEASOME; PYRAZINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; CD8+ T LYMPHOCYTE; DRUG ANTAGONISM; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; NATURAL KILLER CELL; NEOPLASM; REVIEW; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LIGANDS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34848841284     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-72005-0_17     Document Type: Conference Paper

References (18)

1. Almasan, A. and Ashkenazi, A. (2003) Apo2L/TRAIL: Apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14, 337-348.
2. Coulie, P.G., Hanagiri, T. and Takenoyama, M. (2001) From tumor antigens to immunotherapy. Int. J. Clin. Oncol. 6, 163-170.
3. Ganten, T.M., Koschny, R., Haas, T.L., Sykora, J., Li-Weber, M., Herzer, K. and Walczak, H. (2005) Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42, 588-597.
4. Gattinoni, L., Powell, D.J., Rosenberg, S.A. and Restifo, N.P. (2006) Adoptove immunotherapy for cancer: Building on success. Nature 6, 383-393.
5. Gillmore, R., Xue, S-A., Holler, A., Kaeda, J., Hadjiminas, D., Healy, V., Dina, R., Parry, S.C., Bellantuono, I., Ghani, Y., Coombes, R.C., Waxman, J. and Strauss, H.J. (2006) Detection of Wilms' tumor antigen-specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Human Cancer Biol. 12, 34-42.
6. Gottschalk, S., Hislop, H.E. and Rooney, C.M. (2005) Adoptive immunotherapy of EBVassociated malignancies. Leuk. Lymphoma 46, 1-10.
7. Peng, L., Krauss, J.C., Plautz, G.E., Mukai, S., Shu, S. and Cohen, P.A. (2000) T cellmediated tumor rejection displays diverse dependence upon perforin and IFN-? mechanisms that cannot be predicted from in vitro T cell characteristics. J. Immunol. 165, 7116-7124.
8. Poehlein, C.H., Hu, H-M., Yamada, J., Assmann, I., Alvord, W.G., Urba, W.J. and Fox, B.A. (2003) TNF plays an essential role in tumor regression after adoptive transfer of perforin /IFN-? double knockout effector T cells. J. Immunol. 170, 2004-2013.
9. Qin, Z. and Blankenstein, T. (2000) CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN-? receptor expression by nonhematopoetic cells. Immunity 12, 677-686.
10. Rosenberg, S.A., Yang, J.C. and Restifo,N.P. (2004) Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10, 909-915.
11. Ryschich, E., Notzel, T., Hinz, U, Autschbach, F., Ferguson, J., Simon, I., Weitz, J., Frohlich, B., Klar, E., Buchler, M.W. and Schmidt, J. (2005) Control of T cell-mediated immune response by HLA class I in human pancreatic cancer. Clin. Cancer Res. 11, 498-504.
12. Sayers, T.J., Brooks, A.D., Koh, C.Y., Ma, W., Seki, N., Raziuddin, A. Blazar, B.R., Zhang, X., Elliott, P.J. and Murphy, W.J. (2003) The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102, 303-310.
13. Sayers, T.J. and Murphy, W.J. (2006) Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol. Immunother. 55, 76-84.
14. Seki, N., Brooks, A.D., Carter, C.R.D., Back,T.C., Parsoneault, E.M., Smyth, M.J., Wiltrout, R.H. and Sayers, T.J. (2002) Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J. Immunol. 168, 3484-3492.
15. Spiotto, M.T., Rowley, D.A. and Schrieber, H. (2004) Bystander elimination of antigen loss Variants in established tumors. Nat. Med. 10, 294-298.
16. Sun, K., Welniak, L., Panoskaltsis-Mortari, A., O'Shaughnessy, M.J., Liu, H., Barao, I., Riordan, W., Sitcheran, R., Wysocki, C., Serody, J.S., Blazar, B.R., Sayers, T.J. and Murphy, W.J. (2004) Inhibition of acute graft-versus-host disease with retention of graft -versustumor effects by the proteasome inhibitor bortezomib. Proc. Natl. Acad. Sci. U.S.A. 101,8120-8125.
17. Voskoboinik, I. and Trapani, J.A. (2006) Addressing the mysteries of perforin function. Immunol. and Cell Biol. 84, 66-71.
18. Winter, H., Hu, H-M., Urba, W.J. and Fox, B.A. (1999) Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (Apo-1L/CD95L). J. Immunol. 163, 4462-4472.